Skip to main content

Table 2 Maternal and neonatal outcomes after FET in women with NC, HRT and OI group

From: Increased risk of maternal and neonatal complications in hormone replacement therapy cycles in frozen embryo transfer

 NCHRTOIP-value
Maternal outcomes
 HDP, n. (%)166 (3.5)a130 (7.9)c24 (4.6)< 0.001*
 GDM, n. (%)247 (5.2)b106 (6.5)39 (7.5)0.030*
 Placenta previa, n. (%)47 (1.0)24 (1.5)6 (1.2)0.299
 Oligohydramnios, n. (%)61 (1.3)17 (1.0)9 (1.7)0.437
Neonatal outcomes
 Gestational age (weeks)
   < 3239 (0.6)b18 (1.1)8 (1.5)0.023*
  32–36+ 6188 (4.0)a,b111 (6.8)32 (6.2)< 0.001*
   ≥ 374510 (95.4)a,b1513 (92.1)477 (92.3)< 0.001*
  LBW, n. (%)130 (2.8)a74 (4.5)19 (3.7)0.002*
  SGA, n. (%)165 (3.5)48 (2.9)26 (5.0)0.073
  LGA, n. (%)1104 (23.4)430 (26.2)c114 (22.1)0.040*
 Gender of neonates n. (%)   0.890
  Male, n. (%)2500 (52.9)863 (52.6)278 (53.8) 
  Female, n. (%)2227 (47.1)779 (47.4)239 (46.2) 
  1. FET frozen embryo transfer, NC natural cycle, HRT hormone replacement therapy, OI ovulation induction, HDP hypertensive disorders of pregnancy, GDM gestational diabetes mellitus, LBW low birth weight, SGA small for gestational age, LGA large for gestational age
  2. *There were significant differences among the three groups
  3. a There were significant differences between NC and HRT group
  4. b There were significant differences between NC and OI group
  5. c There were significant differences between HRT and OI group